contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


izafe-has-been-granted-a-new-patent-for-safer-medication-handling-at-home

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

iZafe Group is a Life Science company focused on the development and marketing of digital medical solutions for home medication management. The company offers, among other things, a medication robot, SaaS solutions and a connected dosing bag. The products aim to reduce the risk of medication errors. Customers include individuals, pharmaceutical companies and public and private healthcare providers globally. iZafe Group is headquartered in Stockholm.

Izafe Group

iZafe Group AB (publ.) announces that the Swedish Patent and Registration Office (PRV) intends to grant another patent application of iZafe Group. The patent, titled "System and procedure for...

<div class="mfn-preamble"><p><strong>iZafe Group AB (publ.) announces that the Swedish Patent and Registration Office (PRV) intends to grant another patent application of iZafe Group. The patent, titled "System and procedure for medication delivery arranged to adjust a pre-defined and pre-packaged medication dose based on a patient-specific parameter," applies to the company's technology for medical and digital security solutions to create safer medication management in the home.</strong></p></div><div class="mfn-body"><p>"This patent gives us additional protection in Sweden for medication handling at home. After the acquisition of Pilloxa, we are able to offer solutions for safe medication for the entire patient journey, which in practice means the following steps:<br>• Pill jars or other loose medicine in syringes, tablets or liquid form. Where, with the help of our app, we remind, show statistics and can send alarms.<br>• Sorting in "dosett" where we offer a smart connected version that, with the help of our app, helps with sorting, reminders, alarms and statistics.<br>• Medication in sachets where, with the help of Dosell, we automate the entire process in the medication.<br>With this patent, we can also create a unique solution for safer medication handling in the home and addressing a significent and increasing demand" says Anders Segerström, CEO of iZafe Group.</p></div><div class="mfn-footer mfn-contacts mfn-56636653838f"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Anders&nbsp;Segerström, Chief Executive Officer&nbsp;<br>E-mail: <a rel="noopener" href="mailto:anders.segerstrom@izafegroup.com">anders.segerstrom@izafegroup.com</a><br>Phone&nbsp;number: <a rel="noopener">+46 70-875 14 12</a><br><br>iZafe Group AB (publ.) <br>Södra Fiskartorpsvägen 20<br>114 33 Stockholm</p><p>E-mail:&nbsp;<a rel="noopener" href="mailto:ir@izafegroup.com">ir@izafegroup.com</a><br><a rel="noopener" href="http://www.izafe.se/investor-relations/">www.izafe.se/investor-relations/</a></p></div><div class="mfn-footer mfn-about mfn-2ae9e9120422"><p><strong class="mfn-heading-1">About Us</strong></p><hr><p>iZafe Group is a Swedish&nbsp;Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The&nbsp;company’s digital&nbsp;medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care&nbsp;personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life.&nbsp;Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.</p><p>The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: <a rel="noopener" href="mailto:info@fnca.se">info@fnca.se</a>. Further information is available at <a rel="noopener" href="http://www.izafe.se/investor-relations/">www.izafe.se/investor-relations/</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/88574d56-c197-4e5b-a5a6-67690157b5d9/izafe-has-been-granted-a-new-patent-for-safer-medication-handling-at-home.pdf" class="mfn-generated mfn-primary">iZafe has been granted a new patent for safer medication handling at home</a></p></div>